FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

· · · · · · · · · · · · · · · · · · ·	 		

ı	OIVID APPROVAL									
ı	OMB Number:	3235-028								
	Estimated average burd	len								

hours per response:

0.5

Check this box if no longer subject to
Section 16. Form 4 or Form 5
obligations may continue. See
Instruction 1(h)

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

1. Name and Address of Reporting Person*					2. Issuer Name and Ticker or Trading Symbol Kura Oncology, Inc. [KURA]						5. Relationship of Reporting Person(s) to Issuer (Check all applicable)							
GUALBERTO ANTONIO						ixura Oncology, me. [KOKA]						Directo	r		10% Ow	ner		
				— <u> </u>								X Officer below)	(give title		Other (s	pecify		
(Last) (First) (Middle)					3. Date of Earliest Transaction (Month/Day/Year)							Chief Medical Officer						
KURA ONCOLOGY, INC.						01/23/2017						Cinci Wedicai Officei						
11119 N. TORREY PINES ROAD, SUITE 125																		
				4	4. If Amendment, Date of Original Filed (Month/Day/Year)							6. Individual or Joint/Group Filing (Check Applicable						
(Street)												ie)	::	D				
LA JOLI	LA C	A	92037									X Form filed by One Reporting Person Form filed by More than One Reporting						
												Form t Persor		e tnan	One Report	ing		
(City) (State) (Zip)																		
		Та	ble I - Non-D	Derivati	ve Se	ecurities	s Ac	quired, D	isposed o	of, or Be	neficia	ly Owned						
1 Title of 9	Security (Inst	tr 3)	2.	action 2A. Deemed 3. 4. Securities Acquired (A)				ed (A) or	or 5. Amount of 6. Ownership				7. Nature of					
2. 11.00 01 0	occurry (mo	0)	Da	Date (Month/Day/Year)		Execution Date,				ed Of (D) (Instr. 3, 4			es .	s Form	ı: Direct I	ndirect Beneficial		
				(MOIIIII/Day/Teal)		(Month/Day/Yea						Owned F	ollowing (i) (In		nstr. 4) (Ownership		
								Code	Amount	(A) (r Price	Reported Transact	ion(s)		10	Instr. 4)		
						Code	Allount	(D)	11100	(Instr. 3	3 and 4)							
			Table II - De	erivativ	e Sec	urities	Acq	uired, Dis	posed of	, or Ben	eficially	Owned						
			(e.	g., put	s, cal	ls, warr	ants	s, options	converti	ble sec	urities)							
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	cise (Month/Day/Year) ve	Execution Date,	Code (Instr.		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s)	e s ally	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)		
				Code	v	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Share	s	(Instr. 4)	011(3)				
Option to purchase common stock	\$6.15	01/23/2017		A		169,000		(1)	01/22/2027	Common Stock	169,00	0 \$0.00	169,00	00	D			

Explanation of Responses:

1. This option vests in 48 equal monthly installments commencing on the grant date.

Remarks:

<u>Heidi Henson, Attorney-in-fact</u> for Antonio Gualberto

01/25/2017

** Signature of Reporting Person

Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

- * If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.